Association Between A C/A Single Nucleotide Polymorphism of the E-Cadherin Gene Promoter and Transitional Cell Carcinoma of the Bladder

Zhang, X.U.; Ma, Xin; Zhu, Qingguo; Li, Long-Cheng; Chen, Zhong; Ye, Zhangqun

doi:10.1097/01.ju.0000084297.43710.e9

Cited by 29 publications

(22 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five studies [53]–[57], including two updated reports [54], [57], detected the -160C/A polymorphism in urothelial cancer patients, which involved 1,064 cases and 1,124 controls. Overall, the meta-analysis showed that the -160A carriers had a significantly increased risk of developing urothelial cancer (OR = 1.70, 95% CI = 1.11–2.61), and significant heterogeneity was found among the five studies ( Q = 20.37, P = 0.0004, I 2 = 80%).…”

Section: Resultsmentioning

confidence: 99%

Contribution of the -160C/A Polymorphism in the E-cadherin Promoter to Cancer Risk: A Meta-Analysis of 47 Case-Control Studies

Wang

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

BackgroundThe -160C/A polymorphism (rs16260) of E-cadherin, a tumor repressor gene, has been shown to be a tumor susceptibility allele for various types of cancers. Because the significance of this polymorphism to cancer risk has been recognized, there are increasing studies investigating -160C/A in different types of cancers and ethnic populations. However, there is still uncertainty about the level of risk for a variety of cancers.MethodsTo resolve the controversial question raised by these studies as of March 2012 and provide more statistical power for detecting the significance of -160C/A, we performed a meta-analysis of 47 case-control studies in 16 types of cancers (18,194 cases and 20,207 controls). A meta-regression model and subgroup analysis were employed to identify the source of heterogeneity. Publication bias was evaluated, and sensitivity analysis and cumulative evidence assessment were also performed.ResultsUsing fixed- and random-effects models, the -160AA homozygote was more susceptible to urothelial cancer compared with the -160CA heterozygote. Additionally, the -160A allele is an ethnicity-dependent risk factor for prostate and colorectal cancers. Carriers of the -160A allele in Asians and Europeans were more susceptible to prostate cancer, whereas their North American counterparts seemed tolerant. The -160AA homozygote plays a protective role for Europeans who develop colorectal cancer. The stability of these observations was confirmed by a one-way sensitivity analysis. However, the cumulative evidence for all cancer types was considered ‘weak’ using the Venice guidelines.ConclusionsA meta-analysis indicated that the -160A allele of E-cadherin provides a higher risk for the development of prostate and urothelial cancers and a protective role for colorectal cancer in an ethnicity-dependent manner.

show abstract

Section: Resultsmentioning

confidence: 99%

Contribution of the -160C/A Polymorphism in the E-cadherin Promoter to Cancer Risk: A Meta-Analysis of 47 Case-Control Studies

Wang

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…It has been hypothesized that the promoter region of the CDH1 gene is responsible for interindividual variation in the production of CDH1 and in turn leads to individual susceptibility to various cancers (Chik et al, 2011). Many previous genetic studies have also suggested that CDH1 promoter polymorphism -160C/A may play an important role in bladder carcinogenesis (Tsukino et al, 2003;Zhang et al, 2003;Kiemeney et al, 2006;Ma et al, 2008). There is a compelling biological rationale for using CDH1 promoter polymorphism and DNA methylation to hinder tumor recurrence, progression, and development of metastases in bladder cancer.…”

Section: Discussionmentioning

confidence: 96%

Role of CDH1 Promoter Polymorphism and DNA Methylation in Bladder Carcinogenesis: A Meta-Analysis

Wang

Kong²,

Zhang³

et al. 2014

DNA and Cell Biology

View full text Add to dashboard Cite

Increasing scientific evidences suggest that CDH1 gene promoter polymorphism and DNA methylation may contribute to the development and progression of bladder cancer, but many existing studies have yielded inconclusive results. This meta-analysis aims to assess the role of CDH1 gene promoter polymorphism and methylation in bladder carcinogenesis. An extensive literature search for relevant studies was conducted in PubMed, Embase, Web of Science, Cochrane Library, and CBM databases from their inception through April 1, 2013. This meta-analysis was performed using the STATA 12.0 software. The crude odds ratio with 95% confidence interval was calculated. Fifteen studies were included in this meta-analysis with a total of 824 bladder cancer patients and 818 healthy controls being assessed. Our meta-analysis revealed that the A variant of CDH1 -160C/A polymorphism was associated with an increased risk of bladder cancer. Further analysis by pathological subtype indicated that patients with invasive carcinoma had a higher frequency of CDH1 -160A variant than those with superficial carcinoma. We analyzed the methylation frequency of CDH1 gene in 608 bladder cancer samples and 338 normal bladder samples. Our data strongly suggest that the CDH1 promoter methylation frequencies in bladder cancer tissues were greater than those in normal control tissues. In conclusion, our meta-analysis indicates that promoter polymorphism and methylation of CDH1 gene may be involved in the development and progression of bladder cancer. CDH1 gene promoter polymorphism and methylation might be promising biomarkers for the diagnosis and prognosis of bladder cancer.

show abstract

“…CDH1-160 SNPs reveals conflicting results. For example, Verhage et al [31] and Zhang et al [32] reported that the A allele carriers had an increased risk of prostate and bladder cancer, respectively, while Tsukino et al [33] showed that CDH1-160 SNPs are not related to the incidence and progression of prostate cancer in the Japanese population. Likewise, in the current HCC results and previous studies on colorectal [30] or gastric cancer [34] reveal that CDH1-160 SNPs may not be genetic markers to identify individuals at higher risk for these diseases.…”

Section: Discussionmentioning

confidence: 97%

Effects of E‐cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma

Chien

Yeh

et al. 2011

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Association Between A C/A Single Nucleotide Polymorphism of the E-Cadherin Gene Promoter and Transitional Cell Carcinoma of the Bladder

Abstract: The -160 C/A single nucleotide polymorphism of the E-cadherin gene promoter is associated with TCCB. This single nucleotide polymorphism may serve as a prognostic marker of TCCB.

Cited by 29 publications

References 11 publications

Contribution of the -160C/A Polymorphism in the E-cadherin Promoter to Cancer Risk: A Meta-Analysis of 47 Case-Control Studies

Contribution of the -160C/A Polymorphism in the E-cadherin Promoter to Cancer Risk: A Meta-Analysis of 47 Case-Control Studies

Role of CDH1 Promoter Polymorphism and DNA Methylation in Bladder Carcinogenesis: A Meta-Analysis

Effects of E‐cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma

Contact Info

Product

Resources

About